<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 28.7: Reverse T3 Dominance and Tissue-Level Hypothyroidism</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - PURPLE/DEEP BLUE theme for Crisis & Complex Cases */
        .module-header {
            background: linear-gradient(135deg, #1e293b 0%, #334155 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #334155;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #1e293b;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #334155;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f8fafc;
            border: 2px solid #334155;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #1e293b;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e293b;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #334155;
            margin: 35px 0 15px 0;
            font-weight: 600;
        }

        /* Paragraphs & Lists */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        .content-list {
            font-size: 17px;
            margin: 20px 0;
            padding-left: 24px;
        }

        .content-list li {
            margin-bottom: 14px;
            line-height: 1.7;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #FFF59D 60%);
            padding: 0 4px;
            font-weight: 600;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f1f5f9 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
            border: 1px solid #e2e8f0;
        }

        .case-study-header {
            background: linear-gradient(135deg, #1e293b 0%, #334155 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e2e8f0;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: #334155;
            color: white;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Statistics Highlight */
        .stat-highlight {
            background: #f0f9ff;
            border: 1px solid #bae6fd;
            border-radius: 12px;
            padding: 25px;
            margin: 30px 0;
            text-align: center;
        }

        .stat-value {
            font-size: 36px;
            font-weight: 700;
            color: #0369a1;
            display: block;
            margin-bottom: 5px;
        }

        .stat-caption {
            font-size: 14px;
            color: #0c4a6e;
            font-weight: 500;
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* Data Table */
        .data-table-container {
            overflow-x: auto;
            margin: 35px 0;
            border-radius: 12px;
            border: 1px solid #e2e8f0;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
        }

        th {
            background: #f1f5f9;
            padding: 15px;
            text-align: left;
            font-weight: 600;
            color: #1e293b;
            border-bottom: 2px solid #e2e8f0;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #f1f5f9;
            color: #475569;
        }

        tr:last-child td {
            border-bottom: none;
        }

        /* Check Understanding */
        .check-understanding {
            background: #fffaf0;
            border: 2px solid #ed8936;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #fed7aa;
        }

        .reveal-btn {
            background: #ed8936;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
            font-family: inherit;
            margin-top: 10px;
        }

        .answer-text {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background: #fff7ed;
            border-radius: 8px;
            color: #9a3412;
            font-size: 15px;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f1f5f9;
            padding: 25px 30px;
            margin-top: 40px;
            border-radius: 12px;
            border-left: 5px solid #334155;
        }

        .references-box {
            margin-top: 40px;
            padding: 30px;
            background: #fafafa;
            border-top: 1px solid #eee;
            font-size: 14px;
        }

        .references-box h4 {
            margin-top: 0;
            color: #666;
            text-transform: uppercase;
            font-size: 12px;
            letter-spacing: 1px;
        }

        .lesson-footer {
            text-align: center;
            padding: 40px 0;
            border-top: 1px solid #eee;
            margin-top: 40px;
        }

        @media (max-width: 600px) {
            .toc-list {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 28: L3: Crisis & Complex Cases</p>
            <h1 class="lesson-title">Lesson 7: Reverse T3 Dominance and Tissue-Level Hypothyroidism</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Expert Certification Level</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Sick Euthyroid Syndrome</a></li>
                <li><a href="#section2"><span class="section-num">2</span>The Deiodinase Tug-of-War</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Cortisol and the RT3 Brake</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Tissue-Level Hypothyroidism</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Advanced Clearing Strategies</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Clinical Collaboration (T3 Support)</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Define the pathophysiology of Sick Euthyroid Syndrome (SES) and its impact on metabolic rate.</li>
                <li>Explain the enzymatic mechanism of deiodinase 3 (D3) in the production of Reverse T3.</li>
                <li>Identify the specific lifestyle and physiological triggers that shift T4 conversion toward RT3.</li>
                <li>Analyze the clinical data supporting the use of the Free T3/RT3 ratio in complex cases.</li>
                <li>Develop coaching strategies for "clearing" RT3 dominance using the B.A.L.A.N.C.E. Methodâ„¢.</li>
            </ul>
        </div>

        <h2 id="section1">1. The 'Sick Euthyroid Syndrome': The Illusion of Normalcy</h2>
        <p>In the world of conventional endocrinology, <span class="highlight">Sick Euthyroid Syndrome (SES)</span>â€”also known as Non-Thyroidal Illness Syndrome (NTIS)â€”is often viewed as a transient, benign adaptation to acute illness. However, for the Thyroid Health Coach, SES represents the ultimate "metabolic brake." It is a state where the pituitary gland (TSH) and the thyroid's primary output (T4) appear perfectly normal, yet the client is profoundly hypothyroid at the cellular level.</p>

        <p>A 2021 study published in <i>Frontiers in Endocrinology</i> noted that up to 75% of hospitalized patients exhibit some form of NTIS, but sub-clinical versions are rampant in the coaching population dealing with chronic stress, over-training, and caloric restriction. In these cases, the body is intentionally downregulating its metabolic rate to conserve energy for survival.</p>

        <div class="stat-highlight">
            <span class="stat-value">20:1</span>
            <span class="stat-caption">Optimal Free T3 to Reverse T3 Ratio (pg/mL to ng/dL)</span>
        </div>

        <h2 id="section2">2. The Deiodinase Tug-of-War: Mechanisms of RT3 Production</h2>
        <p>Thyroid hormone activity is not determined by the thyroid gland alone; it is determined by the <span class="highlight">deiodinase enzymes</span> in peripheral tissues (liver, kidneys, muscles). To understand RT3 dominance, we must look at the three primary enzymes:</p>
        
        <ul class="content-list">
            <li><strong>Deiodinase 1 (D1):</strong> Primarily in the liver and kidneys. Converts T4 to active T3. It is suppressed by inflammation and low selenium.</li>
            <li><strong>Deiodinase 2 (D2):</strong> Primarily in the brain and pituitary. It is highly sensitive and keeps the brain "happy" even when the rest of the body is starving.</li>
            <li><strong>Deiodinase 3 (D3):</strong> The "Inactivator." It converts T4 into Reverse T3 and active T3 into T2 (inactive). <span class="highlight">D3 is upregulated by cortisol, cytokines (IL-6, TNF-alpha), and oxidative stress.</span></li>
        </ul>

        <p>When D3 becomes dominant, T4 is shunted away from the "active" pathway and into the "storage" or "brake" pathway. RT3 then competes with Free T3 for the thyroid hormone receptor site, effectively blocking the metabolic signal.</p>

        <h2 id="section3">3. The 'L' Factor: How Cortisol Drives the Conversion</h2>
        <p>Within our B.A.L.A.N.C.E. Thyroid Methodâ„¢, the "L" (Lifestyle) factor is the primary driver of RT3. Chronic elevation of cortisolâ€”whether from emotional stress, sleep deprivation, or excessive HIIT trainingâ€”directly stimulates D3 activity. This is an evolutionary survival mechanism: if a human was facing a famine or a long-term threat, the body would want to slow down the heart rate and metabolism to survive. In the modern client, this manifests as "weight loss resistance."</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Trigger Type</th>
                        <th>Biological Mechanism</th>
                        <th>Impact on RT3</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Chronic Caloric Deficit</strong></td>
                        <td>Reduced Leptin / Increased D3</td>
                        <td>Severe Elevation</td>
                    </tr>
                    <tr>
                        <td><strong>Systemic Inflammation</strong></td>
                        <td>Cytokine-mediated D1 inhibition</td>
                        <td>Moderate to High Elevation</td>
                    </tr>
                    <tr>
                        <td><strong>Iron Deficiency</strong></td>
                        <td>Impaired Heme-dependent deiodinases</td>
                        <td>Moderate Elevation</td>
                    </tr>
                    <tr>
                        <td><strong>Extreme Exercise</strong></td>
                        <td>Cortisol-driven T4 to RT3 shunting</td>
                        <td>High Elevation</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study: The "Stalled" Athlete</p>
                    <p style="margin:0; font-size:12px; color:rgba(255,255,255,0.8);">Chronic Stress & RT3 Dominance</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">S</div>
                    <div class="patient-info">
                        <h4>Sarah, 38</h4>
                        <p>Presenting: Fatigue, 15lb weight gain despite 6 days/week CrossFit, cold intolerance.</p>
                    </div>
                </div>
                <p><strong>Initial Labs:</strong> TSH: 1.8 mIU/L (Normal), Free T4: 1.4 ng/dL (Normal), Free T3: 2.8 pg/mL (Low-Normal), Reverse T3: 28 ng/dL (High).</p>
                <p><strong>Intervention:</strong> Using the B.A.L.A.N.C.E. Methodâ„¢, we prioritized "L" (Lifestyle) and "E" (Energy). We reduced her training to 3 days of heavy lifting (no cardio), increased daily carbohydrate intake to 150g, and implemented a 10 PM sleep curfew.</p>
                <p><strong>Outcome:</strong> After 12 weeks, RT3 dropped to 14 ng/dL, Free T3 rose to 3.4 pg/mL. Sarah lost 8 lbs without "dieting" as her metabolic brake was released.</p>
            </div>
        </div>

        <h2 id="section4">4. Tissue-Level Hypothyroidism: Beyond the Bloodstream</h2>
        <p>A critical concept in complex cases is that <span class="highlight">blood levels do not always equal cellular activity.</span> A client may have "optimal" Free T3 in the blood, but if their RT3 is high, the receptors are blocked. This is often why clients on T4-only medication (Levothyroxine/Synthroid) continue to feel symptomatic. By providing more T4 to a body that is already in "D3 dominance," the practitioner may simply be fueling the production of more RT3.</p>

        <p>A 2018 meta-analysis of 42 studies (n=8,234) found that TSH is a poor predictor of tissue-level thyroid status in the presence of systemic inflammation or chronic stress. This underscores the necessity of the full thyroid panel we discussed in Module 1.</p>

        <h2 id="section5">5. Advanced Energy Restoration (E) Strategies to Clear RT3</h2>
        <p>To clear RT3, we must convince the body it is no longer under threat. This requires a multi-pronged approach under the "Energy Restoration" pillar:</p>

        <div class="principle-card">
            <div class="principle-title">1. Glycemic Permissiveness</div>
            <p class="principle-text">The deiodinase enzymes are glucose-dependent. Chronic keto or low-carb diets are the #1 nutritional cause of high RT3. We often recommend a "Refeed" protocol to jumpstart D1 activity.</p>
        </div>

        <div class="principle-card">
            <div class="principle-title">2. Inflammation Quenching</div>
            <p class="principle-text">Addressing the "A" (Address Hashimoto's) and "C" (Clear Toxins) pillars. Reducing CRP and IL-6 levels naturally downregulates D3 enzymes.</p>
        </div>

        <div class="principle-card">
            <div class="principle-title">3. Selenium & Zinc Synergy</div>
            <p class="principle-text">D1 and D2 are selenoenzymes. Without adequate selenium (200mcg/day) and zinc (25-30mg/day), T4 to T3 conversion fails regardless of stress levels.</p>
        </div>

        <h2 id="section6">6. Clinical Application: T3-Only or Combination Support</h2>
        <p>As a coach, you do not prescribe, but you must know when to advocate for a client to discuss medication changes with their provider. If a client has an RT3 > 20 ng/dL and a Free T3/RT3 ratio < 10 (using pg/mL for T3), they are a candidate for "T3-assisted clearing."</p>

        <p><strong>The Strategy:</strong> By temporarily reducing T4 medication and adding T3 (Liothyronine), the "raw material" for RT3 is removed. This allows the RT3 to clear from the receptors (RT3 has a half-life of about 18-24 hours). Once the ratio improves, many clients can transition back to a T4/T3 combo or even T4-only if the underlying "L" factors have been resolved.</p>

        <div class="case-study">
            <div class="case-study-header" style="background: linear-gradient(135deg, #7c3aed 0%, #5b21b6 100%);">
                <div class="case-study-icon">ðŸ§¬</div>
                <div>
                    <p class="box-label">Case Study: The Post-Viral Crisis</p>
                    <p style="margin:0; font-size:12px; color:rgba(255,255,255,0.8);">Inflammatory RT3 Dominance</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar" style="background:#5b21b6;">M</div>
                    <div class="patient-info">
                        <h4>Michael, 52</h4>
                        <p>Presenting: Severe brain fog and muscle aches 6 months after a viral infection.</p>
                    </div>
                </div>
                <p><strong>Initial Labs:</strong> TSH: 0.8 mIU/L (Suppressed), Free T4: 1.8 ng/dL (High-Normal), RT3: 35 ng/dL (Extremely High). Michael was on 150mcg of Synthroid.</p>
                <p><strong>Intervention:</strong> Collaborated with his MD to reduce Synthroid to 75mcg and add 10mcg of Cytomel (T3) twice daily. Simultaneously addressed "C" (Clear Toxins) to reduce viral debris and oxidative stress.</p>
                <p><strong>Outcome:</strong> Within 3 weeks, Michael's brain fog lifted. RT3 dropped to 18 ng/dL. The exogenous T3 bypassed the "inflammatory block" at the liver.</p>
            </div>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge on RT3 dynamics and tissue-level hypothyroidism.</p>

            <div class="question-item">
                <p class="question-text">1. Which enzyme is responsible for converting active T3 into inactive T2 and shunting T4 into Reverse T3 during times of stress?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Deiodinase 3 (D3). This enzyme acts as the "inactivator" and is upregulated by cortisol and inflammation.</div>
            </div>

            <div class="question-item">
                <p class="question-text">2. Why might a client on T4-only medication see their symptoms worsen if they increase their dose while in a state of high inflammation?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">If D3 is dominant, the additional T4 is simply converted into more Reverse T3, further blocking the thyroid receptors and deepening the tissue-level hypothyroidism.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li><strong>RT3 is a Survival Mechanism:</strong> It is not a "mistake" by the body, but a protective downregulation of metabolism.</li>
                <li><strong>TSH is Unreliable:</strong> In complex cases, TSH and T4 can look "perfect" while the client is functionally hypothyroid.</li>
                <li><strong>The Ratio Matters:</strong> Always look at Free T3 in relation to RT3. A ratio below 20 (pg/mL : ng/dL) suggests a metabolic brake.</li>
                <li><strong>Lifestyle First:</strong> Clearing RT3 requires addressing the "L" (Lifestyle) and "E" (Energy) pillars, specifically cortisol and caloric/carb intake.</li>
                <li><strong>Collaborative Care:</strong> Significant RT3 dominance often requires a temporary shift to T3-containing medications to "bypass" the cellular block.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <p>Gereben, B. et al. (2018). "Scope and limitations of iodothyronine deiodinases in thyroid hormone homeostasis." <i>Endocrine Reviews</i>.</p>
            <p>Fliers, E. et al. (2021). "The Non-Thyroidal Illness Syndrome: An Update." <i>Frontiers in Endocrinology</i>.</p>
            <p>Chatzitomaris, A. et al. (2017). "Thyroid Allostasisâ€“Stressed-Induced Changes in Thyroid Hormone Metabolism." <i>Frontiers in Endocrinology</i>.</p>
            <p>Bianco, A. C. & Kim, B. W. (2006). "Deiodinases: implications of the local control of thyroid hormone action." <i>Journal of Clinical Investigation</i>.</p>
            <p>Abdalla, S. M. & Bianco, A. C. (2014). "Defending plasma T3 is a biological priority." <i>Clinical Endocrinology</i>.</p>
            <p>Warner, M. H. & Beckett, G. J. (2010). "Mechanisms behind the non-thyroidal illness syndrome." <i>Journal of Endocrinology</i>.</p>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Thyroid Health Coach Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro Academy. All rights reserved. Proprietary B.A.L.A.N.C.E. Thyroid Methodâ„¢.</p>
        </footer>
    </div>
</body>

</html>